DORC Launches Eva Nexus
DORC International announced the launch of Eva Nexus, a device designed to improve efficiency and control in retina, cataract and combined surgery. Eva Nexus introduces multiple innovations in surgical performance and efficiency, including SmartIOP that combines with the existing EquiPhaco technology for optimized control in cataract surgery; Eva Aveta, a trocar cannula system, and Eva Inicio, the first approved micro-injection system.
During the limited release phase, surgeons have performed more than 1,500 surgical procedures with Eva Nexus. The first randomized controlled trial of 250 cases with Eva Nexus will be completed by March 2022.
The detailed highlights of the launch include:
SmartIOP - a highly responsive infusion system for cataract surgery, enabling surgeons to work at lower infusion pressures and sustain a stable anterior chamber even in challenging cases. Future SmartIOP developments will include refinements of IOP control for posterior chamber surgery.
Dynamic Flow Rate and range of EquiPhaco needle and sleeves, Eva Nexus improves efficiency in phaco energy and reduces effective phaco time[3]
Eva Inicio is the first approved micro-injection system designed for precise, ± 1psi control of sub 1ml injections with complimentary cannula systems for sub-retinal injections
Eva Aveta (available to both users of Eva Nexus and the existing Eva system) includes the push-fit, Hi-Flow infusion connection, laser-etched shaft for scleral retention, and chamfered cannula for smoother insertion. Since initial launch, surgeons have reported improved wound sealing[1] and significantly improved performance[2]
Eva Nexus also features independent irrigation and infusion lines for anterior and posterior surgery ensuring easy switching of surgical phase during combined phacovitrectomy surgery
Eva Nexus features a host of ergonomic and user improvements including active monitoring of BSS levels, vertical and lateral adjustable monitor, a digital overlay and footbrake for repositioning of the system
Eva Nexus also features the Two Dimensional Cutter (TDC), VTi Dual-mode fluidics system, and the dual linear, wireless, fully integrated footswitch
During limited release, EVA Nexus has been in active use in 5 surgical centers and has been used in over 400 vitrectomy and 1500 cataract surgeries[4]
EVA Nexus is available now in CE-marked countries; 510k clearance for the US is expected later in 2022. Further approvals will follow in 2022-23.
"Since mid 2021, I have performed over 300 surgeries with the new EVA Nexus system and it has had a remarkable impact on my surgery," said Prof. Peter Stalmans, UZ Leuven, Belgium, the principal investigator in the first clinical trial with Eva Nexus. "The next generation phaco performance includes SmartIOP, significantly improving anterior chamber stability. Combined with the new infusion system of the EVA Nexus VTi pump, it ensures the system is more responsive and allows me to work at lower infusion pressures improving outcomes for my patients. For combined surgery the independent irrigation and infusion lines enable a new dimension of control of the anterior and posterior chamber. DORC have been ready to listen to my feedback and make rapid improvements to the system – the result, EVA Nexus, is an important advance in the future of ophthalmic surgery."